Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1615 - The prospective study of relation between 5-HIAA/substance P and nausea/vomiting in patients receiving moderately emetogenic chemotherapy

Date

09 Oct 2016

Session

Poster display

Presenters

Tetsuhito Muranaka

Citation

Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390

Authors

T. Muranaka1, Y. Komatsu1, S. Ohnishi2, K. Sawada2, K. Harada1, Y. Kawamoto1, H. Nakatsumi1, S. Yuki2, M. Yagisawa3, M. Nakamura3, Y. Kobayashi4, S. Sogabe4, T. Miyagishima4, N. Sakamoto2

Author affiliations

  • 1 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 2 Department Of Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3 Gastroenterology, Sapporo City General Hospital, 060-8604 - Sapporo/JP
  • 4 Medical Oncology, Kushiro Rosai Hospital, Kushiro/JP
More

Resources

Abstract 1615

Background

The use of antagonists of the NK1 and/or 5-HT3 receptor is recommended for the patients receiving high emetogenic chemotherapy (HEC) in order to prevent chemotherapy-induced nausea and vomiting (CINV). Although we widely use them for the patients receiving moderately emetogenic chemotherapy (MEC), supporting evidence is insufficient. We therefore planned to measure the blood concentration of 5-HIAA and substance P in patients receiving MEC, and investigate the relation between their levels and CINV.

Trial design

This is a multicenter exploratory observational research in Japanese patients receiving chemotherapy for gastrointestinal cancer. The key eligibility criteria are as follows: 1) Diagnosed gastrointestinal cancer; 2) Planned to receive high dose cisplatin (for five patients in cohort 1, for validation of measurement), oxaliplatin or irinotecan (for 45 patients in cohort 2); 3) 20 years of age or older; 4) ECOG PS of 0, 1 or 2; 5) Keeping adequate major organ function. By sampling the patients' blood before and 4, 24, 48, 72 and 96 hours after HEC/MEC administration, we measure the changes in blood concentration of substance P and 5-HIAA after chemotherapy, and survey the relevance of blood concentrations of substance P and 5-HIAA and CINV measured by visual analogue scale. This trial is recruiting the patients from 3 institutes from February 2016 to October 2017, and registered as UMIN000021072.

Clinical trial identification

The trial information of this study was registered as UMIN000021072 and released 18th February 2016.

Legal entity responsible for the study

Hokkaido University Hospital

Funding

Ono Pharmaceutical Co., Ltd.

Disclosure

Y. Komatsu: Yoshito Komatsu received honoraria from Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry Co. Ltd., Daiichi–Sankyo Ltd. and Bristol–Myers Squibb. M. Nakamura: Takeda, Chugai Pharma, Bayer Yakuhin, Yakult Honsha, Taiho Pharmaceutical, Lilly Japan, and Kirin Pharmaceuticals. N. Sakamoto: Bristol Myers Squibb and Gilead sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings